respiratory diseases

Pfizer and BioNTech Report Promising Results for mRNA-Based Combination Vaccine Against Influenza and COVID-19

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine…

6 months ago

Novartis division Sandoz expands respiratory medicines portfolio with the acquisition of British company Coalesce Product Development Limited

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and…

2 years ago

Second Phase 3 trial for Dupixent/Dupilumab: the medicine can significantly reduce itch and skin lesions in patients with uncontrolled prurigo nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit…

2 years ago

Roche study combining Esbriet and nintedanib treatment: majority of the patients tolerated the combination treatment

New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each…

7 years ago

Spanish pharmaceutical company Almirall released its H1 2013 financial results

Barcelona, 05-8-2013 — /EuropaWire/ — Almirall’s H1: Executing on growth platforms, financial delivery on track Financial performance in line with guidance…

11 years ago